Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Non-Current Deffered Revenue (2021)

Historic Non-Current Deffered Revenue for ADC Therapeutics (ADCT) over the last 1 years, with Q4 2021 value amounting to $222.7 million.

  • ADC Therapeutics' Non-Current Deffered Revenue changed N/A to $222.7 million in Q4 2021 from the same period last year, while for Dec 2021 it was $222.7 million, marking a year-over-year change of. This contributed to the annual value of $222.7 million for FY2021, which is N/A changed from last year.
  • According to the latest figures from Q4 2021, ADC Therapeutics' Non-Current Deffered Revenue is $222.7 million.
  • In the past 5 years, ADC Therapeutics' Non-Current Deffered Revenue registered a high of $222.7 million during Q4 2021, and its lowest value of $222.7 million during Q4 2021.